Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER

ConclusionsMild-to-moderate COPD is common in patients with HFmrEF/HFpEF and is associated with worse outcomes. The beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, regardless of COPD status.Clinical Trial Registration: ClinicalTrials.gov NCT03619213.

Source: European Journal of Heart Failure - September 1, 2023 Category: Cardiology Authors: Jawad H. Butt, Henri Lu, Toru Kondo, Erasmus Bachus, Rudolf A. de Boer, Silvio E. Inzucchi, Pardeep S. Jhund, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe A. Martinez, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray Tags: Research Article Source Type: research